A PHP Error was encountered

Severity: Warning

Message: fopen(/var/cpanel/php/sessions/ea-php72/ci_sessionc0a42ed464a534af2ac91de7ca9b8c070d67d4b8): failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 176

Backtrace:

File: /home/rejovjcx/mraccuracyreports.com/application/controllers/Reportdetails.php
Line: 10
Function: library

File: /home/rejovjcx/mraccuracyreports.com/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/cpanel/php/sessions/ea-php72)

Filename: Session/Session.php

Line Number: 143

Backtrace:

File: /home/rejovjcx/mraccuracyreports.com/application/controllers/Reportdetails.php
Line: 10
Function: library

File: /home/rejovjcx/mraccuracyreports.com/index.php
Line: 315
Function: require_once

Global Gene Therapy in Cardiovascular Disorder Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

img

Global Gene Therapy in Cardiovascular Disorder Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Gene Therapy in Cardiovascular Disorder Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Gene Therapy in Cardiovascular Disorder report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gene Therapy in Cardiovascular Disorder market is projected to reach US$ 1351.3 million in 2033, increasing from US$ 178 million in 2022, with the CAGR of 21.1% during the period of 2023 to 2033. Demand from Heart Disease and Vascular Disease are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Gene Therapy in Cardiovascular Disorder market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Renovacor
Gene Biotherapeutics
AskBio
Human Stem Cells Institute
Novartis
Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy

Segment by Application


Heart Disease
Vascular Disease
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Gene Therapy in Cardiovascular Disorder market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Gene Therapy in Cardiovascular Disorder introduction, etc. Gene Therapy in Cardiovascular Disorder Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Gene Therapy in Cardiovascular Disorder market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.

Table of Content

1 Market Overview of Gene Therapy in Cardiovascular Disorder
1.1 Gene Therapy in Cardiovascular Disorder Market Overview
1.1.1 Gene Therapy in Cardiovascular Disorder Product Scope
1.1.2 Gene Therapy in Cardiovascular Disorder Market Status and Outlook
1.2 Global Gene Therapy in Cardiovascular Disorder Market Size Overview by Region 2018 VS 2022 VS 2033
1.3 Global Gene Therapy in Cardiovascular Disorder Market Size by Region (2018-2033)
1.4 Global Gene Therapy in Cardiovascular Disorder Historic Market Size by Region (2018-2023)
1.5 Global Gene Therapy in Cardiovascular Disorder Market Size Forecast by Region (2024-2033)
1.6 Key Regions, Gene Therapy in Cardiovascular Disorder Market Size (2018-2033)
1.6.1 North America Gene Therapy in Cardiovascular Disorder Market Size (2018-2033)
1.6.2 Europe Gene Therapy in Cardiovascular Disorder Market Size (2018-2033)
1.6.3 Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Size (2018-2033)
1.6.4 Latin America Gene Therapy in Cardiovascular Disorder Market Size (2018-2033)
1.6.5 Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size (2018-2033)
2 Gene Therapy in Cardiovascular Disorder Market by Type
2.1 Introduction
2.1.1 Viral Gene Therapy
2.1.2 Non-viral Gene Therapy
2.2 Global Gene Therapy in Cardiovascular Disorder Market Size by Type: 2018 VS 2022 VS 2033
2.2.1 Global Gene Therapy in Cardiovascular Disorder Historic Market Size by Type (2018-2023)
2.2.2 Global Gene Therapy in Cardiovascular Disorder Forecasted Market Size by Type (2024-2033)
2.3 Key Regions Market Size by Type
2.3.1 North America Gene Therapy in Cardiovascular Disorder Revenue Breakdown by Type (2018-2033)
2.3.2 Europe Gene Therapy in Cardiovascular Disorder Revenue Breakdown by Type (2018-2033)
2.3.3 Asia-Pacific Gene Therapy in Cardiovascular Disorder Revenue Breakdown by Type (2018-2033)
2.3.4 Latin America Gene Therapy in Cardiovascular Disorder Revenue Breakdown by Type (2018-2033)
2.3.5 Middle East and Africa Gene Therapy in Cardiovascular Disorder Revenue Breakdown by Type (2018-2033)
3 Gene Therapy in Cardiovascular Disorder Market Overview by Application
3.1 Introduction
3.1.1 Heart Disease
3.1.2 Vascular Disease
3.2 Global Gene Therapy in Cardiovascular Disorder Market Size by Application: 2018 VS 2022 VS 2033
3.2.1 Global Gene Therapy in Cardiovascular Disorder Historic Market Size by Application (2018-2023)
3.2.2 Global Gene Therapy in Cardiovascular Disorder Forecasted Market Size by Application (2024-2033)
3.3 Key Regions Market Size by Application
3.3.1 North America Gene Therapy in Cardiovascular Disorder Revenue Breakdown by Application (2018-2033)
3.3.2 Europe Gene Therapy in Cardiovascular Disorder Revenue Breakdown by Application (2018-2033)
3.3.3 Asia-Pacific Gene Therapy in Cardiovascular Disorder Revenue Breakdown by Application (2018-2033)
3.3.4 Latin America Gene Therapy in Cardiovascular Disorder Revenue Breakdown by Application (2018-2033)
3.3.5 Middle East and Africa Gene Therapy in Cardiovascular Disorder Revenue Breakdown by Application (2018-2033)
4 Gene Therapy in Cardiovascular Disorder Competition Analysis by Players
4.1 Global Gene Therapy in Cardiovascular Disorder Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gene Therapy in Cardiovascular Disorder as of 2022)
4.3 Date of Key Players Enter into Gene Therapy in Cardiovascular Disorder Market
4.4 Global Top Players Gene Therapy in Cardiovascular Disorder Headquarters and Area Served
4.5 Key Players Gene Therapy in Cardiovascular Disorder Product Solution and Service
4.6 Competitive Status
4.6.1 Gene Therapy in Cardiovascular Disorder Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Renovacor
5.1.1 Renovacor Profile
5.1.2 Renovacor Main Business
5.1.3 Renovacor Gene Therapy in Cardiovascular Disorder Products, Services and Solutions
5.1.4 Renovacor Gene Therapy in Cardiovascular Disorder Revenue (US$ Million) & (2018-2023)
5.1.5 Renovacor Recent Developments
5.2 Gene Biotherapeutics
5.2.1 Gene Biotherapeutics Profile
5.2.2 Gene Biotherapeutics Main Business
5.2.3 Gene Biotherapeutics Gene Therapy in Cardiovascular Disorder Products, Services and Solutions
5.2.4 Gene Biotherapeutics Gene Therapy in Cardiovascular Disorder Revenue (US$ Million) & (2018-2023)
5.2.5 Gene Biotherapeutics Recent Developments
5.3 AskBio
5.3.1 AskBio Profile
5.3.2 AskBio Main Business
5.3.3 AskBio Gene Therapy in Cardiovascular Disorder Products, Services and Solutions
5.3.4 AskBio Gene Therapy in Cardiovascular Disorder Revenue (US$ Million) & (2018-2023)
5.3.5 Human Stem Cells Institute Recent Developments
5.4 Human Stem Cells Institute
5.4.1 Human Stem Cells Institute Profile
5.4.2 Human Stem Cells Institute Main Business
5.4.3 Human Stem Cells Institute Gene Therapy in Cardiovascular Disorder Products, Services and Solutions
5.4.4 Human Stem Cells Institute Gene Therapy in Cardiovascular Disorder Revenue (US$ Million) & (2018-2023)
5.4.5 Human Stem Cells Institute Recent Developments
5.5 Novartis
5.5.1 Novartis Profile
5.5.2 Novartis Main Business
5.5.3 Novartis Gene Therapy in Cardiovascular Disorder Products, Services and Solutions
5.5.4 Novartis Gene Therapy in Cardiovascular Disorder Revenue (US$ Million) & (2018-2023)
5.5.5 Novartis Recent Developments
6 North America
6.1 North America Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2033)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2033)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Size by Region (2018-2033)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2033)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2033)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gene Therapy in Cardiovascular Disorder Market Dynamics
11.1 Gene Therapy in Cardiovascular Disorder Industry Trends
11.2 Gene Therapy in Cardiovascular Disorder Market Drivers
11.3 Gene Therapy in Cardiovascular Disorder Market Challenges
11.4 Gene Therapy in Cardiovascular Disorder Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Gene Therapy in Cardiovascular Disorder Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2033
Table 2. Global Gene Therapy in Cardiovascular Disorder Market Size by Region (2018-2023) & (US$ Million)
Table 3. Global Gene Therapy in Cardiovascular Disorder Market Size Share by Region (2018-2023)
Table 4. Global Gene Therapy in Cardiovascular Disorder Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 5. Global Gene Therapy in Cardiovascular Disorder Forecasted Market Size Share by Region (2024-2033)
Table 6. Global Gene Therapy in Cardiovascular Disorder Market Size (US$ Million) by Type: 2018 VS 2022 VS 2033
Table 7. Global Gene Therapy in Cardiovascular Disorder Market Size by Type (2018-2023) & (US$ Million)
Table 8. Global Gene Therapy in Cardiovascular Disorder Revenue Market Share by Type (2018-2023)
Table 9. Global Gene Therapy in Cardiovascular Disorder Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 10. Global Gene Therapy in Cardiovascular Disorder Revenue Market Share by Type (2024-2033)
Table 11. North America Gene Therapy in Cardiovascular Disorder Revenue by Type (2018-2023) & (US$ Million)
Table 12. North America Gene Therapy in Cardiovascular Disorder Revenue by Type (2024-2033) & (US$ Million)
Table 13. Europe Gene Therapy in Cardiovascular Disorder Revenue by Type (2018-2023) & (US$ Million)
Table 14. Europe Gene Therapy in Cardiovascular Disorder Revenue by Type (2024-2033) & (US$ Million)
Table 15. Asia-Pacific Gene Therapy in Cardiovascular Disorder Revenue by Type (2018-2023) & (US$ Million)
Table 16. Asia-Pacific Gene Therapy in Cardiovascular Disorder Revenue by Type (2024-2033) & (US$ Million)
Table 17. Latin America Gene Therapy in Cardiovascular Disorder Revenue by Type (2018-2023) & (US$ Million)
Table 18. Latin America Gene Therapy in Cardiovascular Disorder Revenue by Type (2024-2033) & (US$ Million)
Table 19. Middle East and Africa Gene Therapy in Cardiovascular Disorder Revenue by Type (2018-2023) & (US$ Million)
Table 20. Middle East and Africa Gene Therapy in Cardiovascular Disorder Revenue by Type (2024-2033) & (US$ Million)
Table 21. Global Gene Therapy in Cardiovascular Disorder Market Size (US$ Million) by Application: 2018 VS 2022 VS 2033
Table 22. Global Gene Therapy in Cardiovascular Disorder Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global Gene Therapy in Cardiovascular Disorder Revenue Market Share by Application (2018-2023)
Table 24. Global Gene Therapy in Cardiovascular Disorder Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 25. Global Gene Therapy in Cardiovascular Disorder Revenue Market Share by Application (2024-2033)
Table 26. North America Gene Therapy in Cardiovascular Disorder Revenue by Application (2018-2023) & (US$ Million)
Table 27. North America Gene Therapy in Cardiovascular Disorder Revenue by Application (2024-2033) & (US$ Million)
Table 28. Europe Gene Therapy in Cardiovascular Disorder Revenue by Application (2018-2023) & (US$ Million)
Table 29. Europe Gene Therapy in Cardiovascular Disorder Revenue by Application (2024-2033) & (US$ Million)
Table 30. Asia-Pacific Gene Therapy in Cardiovascular Disorder Revenue by Application (2018-2023) & (US$ Million)
Table 31. Asia-Pacific Gene Therapy in Cardiovascular Disorder Revenue by Application (2024-2033) & (US$ Million)
Table 32. Latin America Gene Therapy in Cardiovascular Disorder Revenue by Application (2018-2023) & (US$ Million)
Table 33. Latin America Gene Therapy in Cardiovascular Disorder Revenue by Application (2024-2033) & (US$ Million)
Table 34. Middle East and Africa Gene Therapy in Cardiovascular Disorder Revenue by Application (2018-2023) & (US$ Million)
Table 35. Middle East and Africa Gene Therapy in Cardiovascular Disorder Revenue by Application (2024-2033) & (US$ Million)
Table 36. Global Gene Therapy in Cardiovascular Disorder Revenue (US$ Million) by Players (2018-2023)
Table 37. Global Gene Therapy in Cardiovascular Disorder Revenue Market Share by Players (2018-2023)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gene Therapy in Cardiovascular Disorder as of 2022)
Table 39. Date of Key Players Enter into Gene Therapy in Cardiovascular Disorder Market
Table 40. Global Gene Therapy in Cardiovascular Disorder Key Players Headquarters and Area Served
Table 41. Gene Therapy in Cardiovascular Disorder Product Solution and Service
Table 42. Global Gene Therapy in Cardiovascular Disorder Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Renovacor Basic Information List
Table 45. Renovacor Description and Business Overview
Table 46. Renovacor Gene Therapy in Cardiovascular Disorder Products, Services and Solutions
Table 47. Revenue (US$ Million) in Gene Therapy in Cardiovascular Disorder Business of Renovacor (2018-2023)
Table 48. Renovacor Recent Developments
Table 49. Gene Biotherapeutics Basic Information List
Table 50. Gene Biotherapeutics Description and Business Overview
Table 51. Gene Biotherapeutics Gene Therapy in Cardiovascular Disorder Products, Services and Solutions
Table 52. Revenue (US$ Million) in Gene Therapy in Cardiovascular Disorder Business of Gene Biotherapeutics (2018-2023)
Table 53. Gene Biotherapeutics Recent Developments
Table 54. AskBio Basic Information List
Table 55. AskBio Description and Business Overview
Table 56. AskBio Gene Therapy in Cardiovascular Disorder Products, Services and Solutions
Table 57. Revenue (US$ Million) in Gene Therapy in Cardiovascular Disorder Business of AskBio (2018-2023)
Table 58. AskBio Recent Developments
Table 59. Human Stem Cells Institute Basic Information List
Table 60. Human Stem Cells Institute Description and Business Overview
Table 61. Human Stem Cells Institute Gene Therapy in Cardiovascular Disorder Products, Services and Solutions
Table 62. Revenue (US$ Million) in Gene Therapy in Cardiovascular Disorder Business of Human Stem Cells Institute (2018-2023)
Table 63. Human Stem Cells Institute Recent Developments
Table 64. Novartis Basic Information List
Table 65. Novartis Description and Business Overview
Table 66. Novartis Gene Therapy in Cardiovascular Disorder Products, Services and Solutions
Table 67. Revenue (US$ Million) in Gene Therapy in Cardiovascular Disorder Business of Novartis (2018-2023)
Table 68. Novartis Recent Developments
Table 69. North America Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2023) & (US$ Million)
Table 70. North America Gene Therapy in Cardiovascular Disorder Market Size by Country (2024-2033) & (US$ Million)
Table 71. Europe Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2023) & (US$ Million)
Table 72. Europe Gene Therapy in Cardiovascular Disorder Market Size by Country (2024-2033) & (US$ Million)
Table 73. Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 74. Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Size by Region (2018-2023) & (US$ Million)
Table 75. Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Size by Region (2024-2033) & (US$ Million)
Table 76. Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Share by Region (2018-2023)
Table 77. Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Share by Region (2024-2033)
Table 78. Latin America Gene Therapy in Cardiovascular Disorder Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 79. Latin America Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2023) & (US$ Million)
Table 80. Latin America Gene Therapy in Cardiovascular Disorder Market Size by Country (2024-2033) & (US$ Million)
Table 81. Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 82. Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size by Country (2018-2023) & (US$ Million)
Table 83. Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size by Country (2024-2033) & (US$ Million)
Table 84. Gene Therapy in Cardiovascular Disorder Market Trends
Table 85. Gene Therapy in Cardiovascular Disorder Market Drivers
Table 86. Gene Therapy in Cardiovascular Disorder Market Challenges
Table 87. Gene Therapy in Cardiovascular Disorder Market Restraints
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Therapy in Cardiovascular Disorder Market Size Year-over-Year 2018-2033 & (US$ Million)
Figure 2. Global Gene Therapy in Cardiovascular Disorder Market Size (US$ Million), 2018 VS 2022 VS 2033
Figure 3. Global Gene Therapy in Cardiovascular Disorder Market Share by Regions: 2022 VS 2033
Figure 4. Global Gene Therapy in Cardiovascular Disorder Forecasted Market Size Share by Region (2024-2033)
Figure 5. North America Gene Therapy in Cardiovascular Disorder Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 6. Europe Gene Therapy in Cardiovascular Disorder Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 7. Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 8. Latin America Gene Therapy in Cardiovascular Disorder Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 9. Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 10. Product Picture of Viral Gene Therapy
Figure 11. Global Viral Gene Therapy Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 12. Product Picture of Non-viral Gene Therapy
Figure 13. Global Non-viral Gene Therapy Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 14. Global Gene Therapy in Cardiovascular Disorder Market Size Share by Type: 2022 & 2033
Figure 15. North America Gene Therapy in Cardiovascular Disorder Revenue Market Share by Type (2018-2033)
Figure 16. Europe Gene Therapy in Cardiovascular Disorder Revenue Market Share by Type (2018-2033)
Figure 17. Asia-Pacific Gene Therapy in Cardiovascular Disorder Revenue Market Share by Type (2018-2033)
Figure 18. Latin America Gene Therapy in Cardiovascular Disorder Revenue Market Share by Type (2018-2033)
Figure 19. Middle East and Africa Gene Therapy in Cardiovascular Disorder Revenue Market Share by Type (2018-2033)
Figure 20. Heart Disease Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 21. Vascular Disease Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 22. Global Gene Therapy in Cardiovascular Disorder Market Size Share by Application: 2022 & 2033
Figure 23. North America Gene Therapy in Cardiovascular Disorder Revenue Market Share by Application (2018-2033)
Figure 24. Europe Gene Therapy in Cardiovascular Disorder Revenue Market Share by Application (2018-2033)
Figure 25. Asia-Pacific Gene Therapy in Cardiovascular Disorder Revenue Market Share by Application (2018-2033)
Figure 26. Latin America Gene Therapy in Cardiovascular Disorder Revenue Market Share by Application (2018-2033)
Figure 27. Middle East and Africa Gene Therapy in Cardiovascular Disorder Revenue Market Share by Application (2018-2033)
Figure 28. Gene Therapy in Cardiovascular Disorder Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 29. Global Top 5 and Top 10 Players Gene Therapy in Cardiovascular Disorder Market Share in 2022
Figure 30. North America Gene Therapy in Cardiovascular Disorder Market Share by Country (2018-2033)
Figure 31. United States Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 32. Canada Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 33. Germany Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 34. France Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 35. U.K. Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 36. Italy Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 37. Russia Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 38. Nordic Countries Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 39. Asia-Pacific Gene Therapy in Cardiovascular Disorder Market Share by Region (2018-2033)
Figure 40. China Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 41. Japan Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 42. South Korea Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 43. Southeast Asia Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 44. India Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 45. Australia Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 46. Latin America Gene Therapy in Cardiovascular Disorder Market Share by Country (2018-2033)
Figure 47. Mexico Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 48. Brazil Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 49. Middle East & Africa Gene Therapy in Cardiovascular Disorder Market Share by Country (2018-2033)
Figure 50. Turkey Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 51. Saudi Arabia Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 52. UAE Gene Therapy in Cardiovascular Disorder Market Size (2018-2033) & (US$ Million)
Figure 53. Bottom-up and Top-down Approaches for This Report